A record of what Ajit Banerjee said publicly, with the source. Not advice.
Pending — not yet graded
“Bullish on quality pharma stocks, viewing tariff-induced volatility as an opportunity for investors to accumulate on dips. While US tariff uncertainty poses risks to profitability, India's cost-competitiveness and the unaffected domestic market provide a silver lining. The sector's 1Y forward P/E of 29.7x is above its 10-year average of 26.7x.”
Nifty PharmaBullishCalled 13 Aug 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Ajit Banerjee’s full track record